Aug 20 2026 Freshfields advised Eli Lilly and Company (“Lilly”) on its strategic research collaboration and licensing agreement with Amplitude Therapeutics to discover and develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. Under the agreement, Lilly will receive exclusive, target-specific rights to develop and commercialize licensed products directed to the collaboration targets.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jake
Contact Jake, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack